| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 31 | 2015 | 312 | 3.450 |
Why?
|
| Carcinoma | 7 | 2015 | 96 | 1.290 |
Why?
|
| Neovascularization, Pathologic | 13 | 2015 | 127 | 1.140 |
Why?
|
| Neurosecretory Systems | 2 | 2012 | 16 | 0.740 |
Why?
|
| src-Family Kinases | 4 | 2013 | 46 | 0.700 |
Why?
|
| Mice, Nude | 22 | 2015 | 337 | 0.670 |
Why?
|
| Stress, Psychological | 6 | 2015 | 583 | 0.620 |
Why?
|
| Anoikis | 2 | 2015 | 21 | 0.600 |
Why?
|
| Cell Proliferation | 18 | 2015 | 1198 | 0.530 |
Why?
|
| Integrin beta Chains | 1 | 2015 | 4 | 0.520 |
Why?
|
| Cell Line, Tumor | 24 | 2015 | 2231 | 0.500 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 2013 | 34 | 0.490 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 85 | 0.470 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 4 | 2015 | 19 | 0.460 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2015 | 59 | 0.460 |
Why?
|
| RNA, Small Interfering | 7 | 2015 | 409 | 0.440 |
Why?
|
| Neoplasms | 4 | 2014 | 1103 | 0.440 |
Why?
|
| Norepinephrine | 6 | 2015 | 110 | 0.430 |
Why?
|
| Mice | 27 | 2015 | 5913 | 0.410 |
Why?
|
| Macrophages | 1 | 2015 | 439 | 0.390 |
Why?
|
| Animals | 35 | 2015 | 15081 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2015 | 161 | 0.370 |
Why?
|
| Transcription Factors | 1 | 2015 | 681 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2015 | 807 | 0.350 |
Why?
|
| Estrous Cycle | 1 | 2009 | 35 | 0.340 |
Why?
|
| Gene Silencing | 6 | 2015 | 151 | 0.320 |
Why?
|
| Female | 35 | 2015 | 20969 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2015 | 259 | 0.300 |
Why?
|
| Estrogens | 1 | 2009 | 202 | 0.300 |
Why?
|
| Cell Movement | 5 | 2015 | 571 | 0.300 |
Why?
|
| Estradiol | 1 | 2009 | 262 | 0.290 |
Why?
|
| Antineoplastic Agents | 9 | 2015 | 803 | 0.280 |
Why?
|
| Cisplatin | 4 | 2015 | 72 | 0.280 |
Why?
|
| Disease Progression | 4 | 2014 | 601 | 0.270 |
Why?
|
| Humans | 37 | 2015 | 37093 | 0.270 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 54 | 0.250 |
Why?
|
| Epinephrine | 3 | 2015 | 36 | 0.230 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2014 | 40 | 0.220 |
Why?
|
| Signal Transduction | 8 | 2015 | 1908 | 0.210 |
Why?
|
| Stress, Physiological | 3 | 2013 | 150 | 0.210 |
Why?
|
| Nanoparticles | 3 | 2014 | 318 | 0.190 |
Why?
|
| Adenosine Triphosphatases | 2 | 2013 | 82 | 0.190 |
Why?
|
| Taxoids | 4 | 2014 | 37 | 0.190 |
Why?
|
| Interleukin-6 | 3 | 2012 | 153 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 182 | 0.180 |
Why?
|
| Dopamine | 2 | 2013 | 245 | 0.180 |
Why?
|
| Apoptosis | 10 | 2015 | 1398 | 0.180 |
Why?
|
| Immunohistochemistry | 8 | 2015 | 893 | 0.180 |
Why?
|
| Neoplasm Metastasis | 4 | 2014 | 219 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 122 | 0.170 |
Why?
|
| Paclitaxel | 3 | 2014 | 50 | 0.160 |
Why?
|
| Blotting, Western | 5 | 2015 | 859 | 0.160 |
Why?
|
| Phosphorylation | 4 | 2015 | 928 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2015 | 222 | 0.140 |
Why?
|
| Tyrosine | 2 | 2014 | 118 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 448 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 623 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2015 | 3 | 0.130 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2015 | 7 | 0.130 |
Why?
|
| Phospholipase C gamma | 1 | 2015 | 8 | 0.130 |
Why?
|
| Oncogene Protein v-akt | 1 | 2015 | 20 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2013 | 52 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 3 | 2010 | 108 | 0.130 |
Why?
|
| Aminopyridines | 1 | 2015 | 15 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2014 | 435 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 54 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 22 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 32 | 0.130 |
Why?
|
| Troponin C | 1 | 2014 | 3 | 0.130 |
Why?
|
| Contractile Proteins | 1 | 2014 | 8 | 0.130 |
Why?
|
| Diphosphonates | 1 | 2014 | 10 | 0.120 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2013 | 73 | 0.120 |
Why?
|
| Crk-Associated Substrate Protein | 2 | 2011 | 3 | 0.120 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 54 | 0.120 |
Why?
|
| RNA Interference | 3 | 2011 | 243 | 0.120 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2014 | 2 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 39 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2014 | 34 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 251 | 0.120 |
Why?
|
| Glutamine | 1 | 2014 | 40 | 0.120 |
Why?
|
| Disease Models, Animal | 5 | 2012 | 1371 | 0.120 |
Why?
|
| Phosphates | 1 | 2014 | 51 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 3 | 2010 | 502 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2014 | 106 | 0.120 |
Why?
|
| Cell Survival | 6 | 2015 | 864 | 0.120 |
Why?
|
| Pericytes | 2 | 2013 | 22 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2014 | 80 | 0.110 |
Why?
|
| Transplantation, Heterologous | 5 | 2011 | 90 | 0.110 |
Why?
|
| Phosphoserine | 1 | 2013 | 19 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2014 | 168 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 111 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 158 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 95 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 83 | 0.110 |
Why?
|
| Immunoprecipitation | 2 | 2009 | 131 | 0.100 |
Why?
|
| Thrombocytosis | 1 | 2012 | 5 | 0.100 |
Why?
|
| Microvessels | 2 | 2009 | 28 | 0.100 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2012 | 4 | 0.100 |
Why?
|
| Prognosis | 4 | 2015 | 739 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 2013 | 131 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 325 | 0.100 |
Why?
|
| Monocytes | 1 | 2014 | 257 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2013 | 444 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2011 | 16 | 0.100 |
Why?
|
| Thiazoles | 1 | 2011 | 74 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 28 | 0.090 |
Why?
|
| Autophagy | 1 | 2011 | 116 | 0.090 |
Why?
|
| Adrenergic Agents | 1 | 2010 | 8 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2011 | 118 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2010 | 60 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 82 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2010 | 8 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 132 | 0.090 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 12 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2010 | 31 | 0.090 |
Why?
|
| Cation Transport Proteins | 1 | 2009 | 34 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 41 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 31 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 239 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2014 | 426 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 433 | 0.080 |
Why?
|
| Models, Molecular | 1 | 2013 | 808 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 113 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 81 | 0.080 |
Why?
|
| Psychoneuroimmunology | 1 | 2008 | 2 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 4 | 2012 | 290 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2009 | 136 | 0.080 |
Why?
|
| Neuroimmunomodulation | 1 | 2008 | 13 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2009 | 111 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2009 | 212 | 0.080 |
Why?
|
| Neoplasm Transplantation | 4 | 2011 | 122 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1207 | 0.080 |
Why?
|
| Piperazines | 1 | 2008 | 111 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2007 | 90 | 0.070 |
Why?
|
| Curcumin | 1 | 2007 | 74 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2015 | 269 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2011 | 189 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2010 | 77 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 339 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 935 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2014 | 177 | 0.060 |
Why?
|
| Ki-67 Antigen | 2 | 2015 | 33 | 0.060 |
Why?
|
| Receptors, Dopamine | 2 | 2013 | 25 | 0.050 |
Why?
|
| Actins | 2 | 2014 | 148 | 0.050 |
Why?
|
| Depression | 1 | 2008 | 712 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2015 | 1369 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2014 | 308 | 0.050 |
Why?
|
| Models, Biological | 2 | 2014 | 677 | 0.040 |
Why?
|
| Phosphatidylinositols | 1 | 2015 | 12 | 0.030 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Ribonuclease III | 1 | 2014 | 10 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 13 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 173 | 0.030 |
Why?
|
| Albumins | 1 | 2014 | 26 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 58 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2014 | 49 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 75 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 400 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 98 | 0.030 |
Why?
|
| Middle Aged | 3 | 2013 | 10129 | 0.030 |
Why?
|
| R-SNARE Proteins | 1 | 2013 | 5 | 0.030 |
Why?
|
| Second Messenger Systems | 1 | 2013 | 14 | 0.030 |
Why?
|
| Qa-SNARE Proteins | 1 | 2013 | 9 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2013 | 27 | 0.030 |
Why?
|
| Dopamine Agents | 1 | 2013 | 25 | 0.030 |
Why?
|
| Catecholamines | 1 | 2013 | 44 | 0.030 |
Why?
|
| Benzazepines | 1 | 2013 | 32 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 268 | 0.030 |
Why?
|
| Adult | 3 | 2014 | 11712 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2014 | 326 | 0.030 |
Why?
|
| Thrombopoietin | 1 | 2012 | 4 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Platelet Count | 1 | 2012 | 13 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 251 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 181 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 674 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 16 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2011 | 47 | 0.020 |
Why?
|
| Calcium | 1 | 2014 | 480 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 176 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 77 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 201 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 146 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 85 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2013 | 381 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 208 | 0.020 |
Why?
|
| Restraint, Physical | 1 | 2010 | 20 | 0.020 |
Why?
|
| Chitosan | 1 | 2011 | 36 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2010 | 37 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 441 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 275 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 41 | 0.020 |
Why?
|
| Caspases | 1 | 2011 | 147 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 147 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 523 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 306 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 1095 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 286 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 583 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 148 | 0.020 |
Why?
|
| Aged | 2 | 2011 | 6741 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 252 | 0.020 |
Why?
|
| Propranolol | 1 | 2009 | 18 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2009 | 42 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 43 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 227 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 933 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 513 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 997 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 237 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2011 | 517 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 59 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 48 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 651 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2010 | 325 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 885 | 0.020 |
Why?
|
| Terbutaline | 1 | 2006 | 1 | 0.020 |
Why?
|
| Phthalazines | 1 | 2006 | 3 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2006 | 36 | 0.020 |
Why?
|
| Radiography | 1 | 2006 | 72 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 1609 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2006 | 98 | 0.020 |
Why?
|
| Organ Size | 1 | 2006 | 157 | 0.020 |
Why?
|
| Random Allocation | 1 | 2006 | 139 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 972 | 0.020 |
Why?
|
| Pyridines | 1 | 2006 | 116 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 602 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1039 | 0.020 |
Why?
|
| Male | 1 | 2013 | 20025 | 0.010 |
Why?
|